Stock Taper
SCREENER COMPARE ANY 2 STOCKS
TVRD
TVARDI THERAPEUTICS, INC.
NASDAQ
$1.86
▲ UP 1.64% (0.03)

KEY STATISTICS

Market Cap$17.45 M
52w High$43.65
52w Low$1.50
Dividend Yield—
Frequency—
P/E-0.67
Volume166.83K
Shares Out.9.38M

COMPANY

LEADERSHIP

Imran Alibhai
CHIEF EXECUTIVE
Imran Alibhai

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 31, 2014
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
12

PRICE TARGET

Target High$13.00
Target Low$3.00
Target Median$9.50
Target Consensus$8.75

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

PRICE

$1.86 ▲ UP 1.64% (+$0.03)
$1.83$1.86$1.89$1.929:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM1.86

About Tvardi Therapeutics, Inc.

https://tvarditherapeutics.com ↗

Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing oral STAT3 inhibitors, with TTI-101 in Phase 2 trials for IPF and HCC, targeting fibrosis-driven diseases with unmet medical needs.

INDUSTRY

Biotechnology

A PRODUCT TVARDI THERAPEUTICS, INC. IS KNOWN FOR

TTI-101
TTI-101

TTI-101 is an oral small molecule STAT3 inhibitor, Tvardi's lead candidate in Phase 2 trials for hepatocellular carcinoma (liver cancer).

COMPETITORS

COMPETITOR
MBRX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
11
LISTED HERE
1
RANKED BY POSITION SIZE
VTI
0.00% · 258.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
29.39%
HOLDERS
90
TOP 12 OF 90 · RANKED BY POSITION SIZE
Slate Path Capital LP
704.1K sh · $2.24M
Vanguard Group Inc
424.8K sh · $1.83M
Blackrock, Inc.
391.0K sh · $1.68M
American Financial Group Inc
223.7K sh · $711.24K
Geode Capital Management, LLC
182.3K sh · $579.96K
683 Capital Management, LLC
176.0K sh · $6.77M
Vestal Point Capital, LP
167.0K sh · $6.51M
State Street Corp
115.5K sh · $496.65K
Renaissance Technologies LLC
104.5K sh · $449.35K
Silvercrest Asset Management Group LLC
101.0K sh · $434.45K
Morgan Stanley
84.5K sh · $363.2K
Invesco Ltd.
82.6K sh · $3.22M

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR
Shiff Susan Ph.D.
Purchase · 6.0K shares
2026-06-09
★
DIRECTOR
Smith Cynthia
Purchase · 6.0K shares
2026-06-09
★
DIRECTOR
Shah Sujal
Purchase · 6.0K shares
2026-06-09
★
DIRECTOR
HALL WALLACE L JR
Purchase · 6.0K shares
2026-06-09

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
OUTPERFORM 1
UNDERWEIGHT 1
NEUTRAL 1
4 GRADES IN THE LAST 12 MONTHS
BTIG BUY Raymond James OUTPERFORM Barclays UNDERWEIGHT Piper Sandler NEUTRAL

SECTORS PEERS

PEERPRICE
XLO$9.23COMPARE
ELUT$0.95COMPARE
LTRN$2.34COMPARE
TPST$1.04COMPARE
PDSB$0.22COMPARE
CALC$0.57COMPARE
RVPH$0.48COMPARE